We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

66 hedge funds and large institutions have $18M invested in Protalix BioTherapeutics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

556% more call options, than puts

Call options by funds: $984K | Put options by funds: $150K

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

31% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 16

18% more capital invested

Capital invested by funds: $15.2M → $18M (+$2.79M)

8% more funds holding

Funds holding: 61 → 66 (+5)

1.06% more ownership

Funds ownership: 12.81% → 13.86% (+1.1%)

Holders
66
Holders Change
+5
Holders Change %
+8.2%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
21
Reduced
16
Closed
7
Calls
$984K
Puts
$150K
Net Calls
+$834K
Net Calls Change
-$184K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$467K
2
BlackRock
BlackRock
New York
+$439K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$161K
4
Northern Trust
Northern Trust
Illinois
+$136K
5
Barclays
Barclays
United Kingdom
+$123K

Top Sellers

Rank Fund Capital Flow
1
Allspring Global Investments
Allspring Global Investments
North Carolina
-$229K
2
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$150K
3
XT
XTX Topco
Cayman Islands
-$101K
4
SOW
State of Wyoming
Wyoming
-$68.5K
5
Invesco
Invesco
Georgia
-$45.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$77.8K – – –
HSBC Holdings
27
HSBC Holdings
United Kingdom
$70.9K – – –
SC
28
Sculptor Capital
New York
$65.9K – – –
SG Americas Securities
29
SG Americas Securities
New York
$62K +$7.15K +4,598 +15%
Franklin Resources
30
Franklin Resources
California
$59.7K +$52.2K +33,548 New
AIG
31
American International Group
New York
$58.7K -$205 -132 -0.4%
VOYA Investment Management
32
VOYA Investment Management
Georgia
$52.1K – – –
Jane Street
33
Jane Street
New York
$51.3K +$44.8K +28,825 New
Invesco
34
Invesco
Georgia
$47.9K -$45.9K -29,531 -52%
CPA
35
Capital Performance Advisors
California
$46.2K +$2 +1 +0%
AllianceBernstein
36
AllianceBernstein
Tennessee
$41.7K – – –
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$39K +$16.6K +10,663 +96%
Wells Fargo
38
Wells Fargo
California
$35.5K +$6.24K +4,010 +25%
Two Sigma Investments
39
Two Sigma Investments
New York
$34.9K -$43.1K -27,700 -59%
XT
40
XTX Topco
Cayman Islands
$33.4K -$101K -65,223 -78%
ACA
41
Aptus Capital Advisors
Alabama
$33K +$1.59K +1,025 +6%
State Board of Administration of Florida Retirement System
42
State Board of Administration of Florida Retirement System
Florida
$30.7K +$26.8K +17,228 New
T. Rowe Price Associates
43
T. Rowe Price Associates
Maryland
$29K – – –
Lido Advisors
44
Lido Advisors
California
$27.7K -$467 -300 -2%
FI
45
Finivi Inc
Massachusetts
$25.9K +$22.6K +14,544 New
AS
46
Altshuler Shaham
Israel
$21.6K – – –
TRCT
47
Tower Research Capital (TRC)
New York
$21.2K +$8.05K +5,179 +77%
Citigroup
48
Citigroup
New York
$20.6K +$15K +9,658 +510%
KAS
49
Kestra Advisory Services
Texas
$20.5K – – –
ProShare Advisors
50
ProShare Advisors
Maryland
$19.5K +$17.1K +10,979 New
1
2
3

PLX Hedge Fund Activity: Q4 2023 in Review

66 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2023, worth a combined $18M — up 18% from $15.2M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PLX positions and 7 closed out — a net gain of 5 holders — while 21 added to existing stakes and 16 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $467K. The largest seller was Allspring Global Investments, exiting entirely with an estimated $229K sold.

  • 66 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2023, up from 61 in Q3 2023.
  • Funds reported $18M of Protalix BioTherapeutics stock for Q4 2023, up 18% quarter-over-quarter.
  • 12 funds opened new Protalix BioTherapeutics positions in Q4 2023 and 7 closed out, a net change of +5 holders.
  • The largest Protalix BioTherapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $467K added.
  • The largest Protalix BioTherapeutics seller in Q4 2023 was Allspring Global Investments, an estimated $229K sold.

Based on aggregated 13F filings for Q4 2023.